Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Study tests if lung cancer screening cuts smoking:

This article was originally published in Clinica

Executive Summary

A US team has been awarded $3.6m to find out whether CT screening for lung cancer will encourage cigarette smokers to give up the habit or if it will make them put off the decision even longer. In a 4,000-patient study headed by CT lung cancer screening leader Claudia Henschke, researchers from the Weill Medical College of Cornell University, New York, hope to show that CT screening can be effectively linked to smoking-cessation programmes to enhance the motivation for people to stop smoking. "We want to make screening programmes an economic and life-saving reality," said Dr Henschke. The new funds were made through matching grants of $1.8m respectively from the American Legacy Foundation and the UK's Medicsight Foundation. The study is scheduled to start in June.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT058860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel